CohBar, Inc. Engages Torrey Hills Capital
Firm to target investors focused on microcap markets
MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that it has engaged San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe, California-based investor relations firm specializing in small and micro-cap companies, to provide market awareness and investor relations services to the Company, subject to TSX Venture Exchange acceptance. Torrey Hills Capital has been engaged to increase awareness about CohBar through its established relationships with investment professionals, investment advisors, and money managers focused on the microcap market space.
“We’re continuing our focus on expanding awareness in the investment community,” said CohBar CEO Jon Stern. “We expect that Torrey Hill’s long-established relationships with microcap investors, advisors, and money managers across the US and Canada will enable us to present CohBar’s capabilities and opportunities in person to a wide audience of prospective investors.”
Torrey Hills Capital has been engaged for a term of up to 24 months, and will be entitled to receive a monthly fee of US$5,500 plus pre-approved out-of-pocket expenses. The agreement may be terminated by either party upon 30 days’ notice following an initial 90 day period. In addition, CohBar has agreed to a one-time grant of a warrant to purchase up to 125,000 shares of the Company’s common stock exercisable for a period of three years at a price equal to the higher of the closing price of the Common Shares on the TSX Venture Exchange or the OTCQX Market on the date of issuance. The warrant shall become vested and exercisable in 24 equal monthly installments, provided that Torrey Hills Capital is continuing to provide services on the date of each vesting increment. The warrant shall be subject to the applicable policies of the TSX Venture Exchange.
Torrey Hills Capital currently has no direct or indirect interest in the securities of CohBar, or any right or intent to acquire such an interest except pursuant to the exercise of the above referenced warrant.
The appointment of Torrey Hills Capital as an investor relations consultant of CohBar and the granting of the warrant remain subject to regulatory acceptance of applicable filings with the TSX Venture Exchange.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a leader in the research and development of mitochondria-based therapeutics, an emerging class of drugs for the treatment of diseases associated with aging. MBTs originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. MBTs offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
For additional company information, please visit www.cohbar.com.
About Torey Hills Capital
Torrey Hills Capital was formed in 1998 and is headquartered in Rancho Santa Fe, California. The team of professionals offers experience and expertise in investor relations, corporate communications, non-deal road shows, and market support activities. Torrey Hills Capital specializes in the development and marketing of emerging growth companies which trade in the United States (NYSE, AMEX, and OTC) and in Canada (TSX, TSXV, and CSE). Marketing activities articulate key investment attributes, strategic direction, and financial expectations, which combine to ensure that client market value fully reflects past achievements and future opportunities. Further information is available at www.torreyhillscapital.com.
This news release contains forward-looking statements, including statements concerning: the company’s plans, prospects, resources and capabilities including statements regarding its research and development activities and progress towards optimizing mitochondrial derived peptides and development of therapeutic candidates. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated by CohBar. These risks and uncertainties include CohBar’s ability to retain key personnel, expand its research operations, and successfully advance its drug discovery and development programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Jeff Biunno, 973-841-1233
Source: CohBar, Inc.
Released January 7, 2016